Genovis expands its US operation and signs distribution agreement with BulldogBio Inc.

USA is the single most important market for Genovis’ products. The company marketing strategy is to collaborate with qualified partners whose solid knowledge of the American Life Science industry can intensify marketing of the products and increase sales.

Genovis provides novel technical solutions for Transfection, RNAi, Imaging and Antibody Engineering for customers involved in sophisticated research in the pharmaceutical industry and in the academic research community. BulldogBio, www.bulldog-bio.com, is committed to the US market and can provide an exciting range of scientifically challenging products for Life Science research. The company’s business model is to assist its partners with sales and marketing by focusing in particular on the building of trademark awareness on the market, and to sell products using in-house technical competence combined with immediate support. BulldogBio employees have broad competence in Genovis’ business areas and give priority to efficient service. ”This distribution agreement is another important step for Genovis as we expand on the North American market. The agreement broadens our presence and increases the exposure of our trademark. I am pleased with the opportunities this represents and I look forward to working with BulldogBio with their efficient and experienced team”, says Sarah Fredriksson, CEO Genovis AB. For almost two years the fully owned subsidiary Genovis Inc. has been involved in the building of sales channels in USA. During this period a number of distribution agreements have been entered. Genovis took the decision not to build a sales organization in the US subsidiary, so Genovis Inc. has primarily been focusing on defining key reference customers on the crucially important US market. Since the sales activities are now handled through distributors, Genovis has decided to close down the US subsidiary.

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links